Notch is out — your watchlist beside the MacBook notch, synced with this account.
Learn more ↗We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Alteogen is a biopharmaceutical development specialist that leverages technologies such as antibody-drug conjugate (ADC) technology, recombinant hyaluronidase (Hybrozyme™) technology, and NexP™ fusion protein technology to develop innovative new drugs, biosimilars, and biobetters. Notably, it possesses a platform technology (ALT-B4) that converts intravenous (IV) biopharmaceuticals into subcutaneous (SC) formulations, thereby contributing to enhanced patient convenience. Its main business areas are the development of anticancer drugs and treatments for autoimmune diseases.
알테오젠은 바이오의약품 개발 전문 기업으로, 항체-약물 접합(ADC) 기술, 재조합 히알루로니다제(Hybrozyme™) 기술, 넥스피(NexP™) 융합 단백질 기술 등을 활용하여 혁신 신약, 바이오시밀러, 바이오베터를 개발합니다. 특히, 정맥주사 제형의 바이오의약품을 피하주사 제형으로 변경하는 플랫폼 기술(ALT-B4)을 보유하고 있으며, 이를 통해 환자 편의성을 높이는 데 기여하고 있습니다. 주요 사업 영역은 항암제 및 자가면역질환 치료제 개발입니다.
